[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
February 9, 2011

KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

JAMA. 2011;305(6):564-566. doi:10.1001/jama.2011.85

To the Editor: According to the retrospective analysis of KRAS genotypes and outcome after treatment with cetuximab in patients with chemotherapy-refractory metastatic colon cancer, Dr De Roock and colleagues reported that patients with KRAS codon p.G13D mutations who received cetuximab compared with best supportive care experienced longer progression-free and overall survival.1 In contrast, patients with other KRAS mutations did not appear to benefit from cetuximab. Previously, any type of KRAS mutation indicated a lack of effect of anti-epidermal growth factor receptor monoclonal antibody therapy.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×